• Technology
  • Applications
    • AML – MRD
    • Mutagenesis
    • Collaborate
  • Resources
    • Publications
    • Posters
    • Safety
    • Patents
  • Company
    • Our Team
    • Careers
    • Events
    • News
  • Contact
TwinStrand Biosciences
  • Technology
  • Applications
    • AML – MRD
    • Mutagenesis
    • Collaborate
  • Resources
    • Publications
    • Posters
    • Safety
    • Patents
  • Company
    • Our Team
    • Careers
    • Events
    • News
  • Contact

 

AML Minimal Residual Disease

 

Next-generation sequencing (NGS) is a powerful emerging method for detecting residual acute myeloid leukemia (AML) after treatment. However, current methods produce an abundance of sequencing errors which obscure low-frequency leukemia-defining mutations.

 

The TwinStrand Duplex Sequencing™ AML MRD assay is orders of magnitude more sensitive and specific than other NGS based MRD assays, offering unprecedented opportunities for clinical research and drug development.

 

  • >100-fold higher resolution than other error-corrected NGS methods, revealing more clinically significant mutations
  • The 29 gene, 58kb panel encompasses loci mutated in >93% of adult AML patients
  • Assay enables sub-1/100,000 limit of detection anywhere in target region

Duplex Sequencing MRD Technical Performance

 

The TwinStrand Duplex Sequencing AML MRD assay was used to sequence a serially-diluted mixture of AML mutation-containing DNA to a Duplex depth >1,000,000x. Target clones were identified to levels <1/100,000 with 100% sensitivity and specificity.

Panel Overview

The AML panel encompasses the whole coding region or hotspots in 29 genes recurrently mutated in AML, MDS (myelodysplastic syndrome), and CHIP (clonal hematopoiesis).

 


 

Clonal Hematopoiesis

 

Duplex Sequencing detects dozens of simultaneous CHIP clones per individual with aging.

Scientific Content

 

POSTER: Super CHIP: Duplex Sequencing Reveals Clonal Dynamics in Blood that are Magnitudes more Complex than Previously Recognized

POSTER: Duplex Sequencing for MRD Detection in Acute Myeloid Leukemia

POSTER: Redefining “Gold Standard” Ultra-Sensitive Characterization of Commercial DNA Standards with Duplex Sequencing

Download TwinStrand DuplexSeq AML MRD Solution brochure

Have questions about our
AML-MRD kit?

Contact us

 

TwinStrand Biosciences, Inc.
3131 Elliott Ave, Suite 750 • Seattle, WA 98121 • USA
+1 (877) 202-TWIN

 

For Research Use Only. Not for use in diagnostic procedures.

©2020 TwinStrand Biosciences, Inc. All rights reserved. All trademarks are the property of TwinStrand Biosciences, Inc. or their respective owners.  Legal Notices

  

This website uses cookies to improve your experience. Read More. You can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

American Society of Hematology (ASH)

December 5-8, 2020 – Virtual

 

Poster Presentation

 

“Duplex Sequencing with Patient-Specific Hybrid Capture Panels Reveals Ultra-Low Frequency Measurable Residual Disease in Pediatric Acute Myeloid Leukemia”

 

Presented by Jake Higgins, Senior Scientist – December 6, 2020 7:00 a.m.-3:30 p.m. PST

 

Conference Website

 

Society of Toxicology (SOT)

March 10-14, 2019 – Baltimore, MD

 

Poster Presentations

 

 

View Poster

 

 

Conference Website

 

AACR Annual Meeting – San Diego, CA

March 29-April 3, 2019

 

Poster Presentations

 

 

View Poster

 

 

View Poster

Presentations by CEO Jesse Salk, MD, PhD – AGBT 2020

Ultra-Sensitive Residual Leukemia Detection with Patient-Specific Dupex Sequencing